Analyst: Lundbeck’s patent expirations can cost close to a billion
There is pressure on both the top and bottom line in Lundbeck, says an analyst, and the pressure is growing. The company can expect patent expirations on two drugs to cut almost a billion dollars of the company’s turnover in coming years.
by Leonora Beck
Drug sales in Danish company Lundbeck are still dropping and there is no change on the horizon in the immediate future, says analyst Peter Aabo, Nordic Bioinvestor.com. The general increase in turnover in Q1 was simply facilitated by a rapid growth in licensing revenue from a collaboration agreement with Japanese partner Otsuka and divestiture of a small portfolio of drugs in the US.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Lundbeck launches alcohol pill in UK
For abonnenter
Lundbeck: Employers show an interest in alcohol pill
For abonnenter
.jpg&w=384&q=75)
